Keyphrases
Placebo
100%
Monotherapy
100%
Benign Prostatic Hyperplasia
100%
Serenoa Repens
100%
Cochrane Systematic Review
100%
Confidence Interval
41%
Lower Urinary Tract Symptoms
33%
American Urological Association
33%
Symptom Score
33%
Weighted Mean Difference
33%
Serenoa Repens Extract
25%
I(2)
16%
Adverse Events
16%
Nocturia
16%
Symptom-based
16%
International Prostate Symptom Score
16%
Qmax
16%
Meta-analysis
8%
Randomized Trial
8%
Randomized Controlled Trial
8%
Beta-blockers
8%
Symptom Scale
8%
Dose-escalation Trial
8%
Europe
8%
Urodynamics
8%
Pooled Analysis
8%
Treatment Group
8%
MEDLINE
8%
Embase
8%
White Race
8%
Symptomatic Benign Prostatic Hyperplasia
8%
Short-term Study
8%
Inclusion Criteria
8%
Escalating Dose
8%
Risk Ratio
8%
Cochrane Central Register of Controlled Trials
8%
Inappropriate Treatment
8%
Allocation Concealment
8%
3-point
8%
Treatment Allocation
8%
Maximum Urinary Flow Rate
8%
Phytotherapy
8%
Permixon
8%
5α-reductase Inhibitors
8%
Trial Length
8%
Study Withdrawal
8%
Blinded Treatment
8%
Clinical Outcomes
8%
Severe Symptoms
8%
Urological Symptoms
8%
Enrolees
8%
Medicine and Dentistry
Monotherapy
100%
Systematic Review
100%
Prostate Hypertrophy
100%
Placebo
100%
Serenoa
100%
Lower Urinary Tract Symptom
33%
Sabal Extract
33%
American Urological Association Symptom Index
33%
Adverse Event
16%
International Prostate Symptom Score
16%
Nocturia
16%
Urodynamics
8%
Randomized Controlled Trial
8%
Meta-Analysis
8%
Pooled Analysis
8%
Oxidoreductase
8%
Urine Flow Rate
8%
Phytotherapy
8%
Treatment Group
8%
Primary Outcome
8%
Pharmacology, Toxicology and Pharmaceutical Science
Sabal
100%
Placebo
100%
Prostate Hypertrophy
100%
Monotherapy
100%
Sabal Extract
33%
Lower Urinary Tract Symptom
33%
Adverse Event
16%
Nocturia
16%
Randomized Controlled Trial
8%
Oxidoreductase
8%
Phytotherapy
8%
Treatment Group
8%